UroGen Pharma

URGN

Market cap $1.1B

PRINCETON, N.J., April 08, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.

72.2% Probability of Remaining Event-Free at 24 Months by Kaplan-Meier Analysis After Achieving Complete Response at Three Months (79.6%) PRINCETON, N.J., March 30, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.

PRINCETON, N.J., March 06, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.

UroGen Pharma faces a pivotal period as ZUSDURI, its recently approved bladder cancer therapy, is positioned for accelerated adoption following a permanent J-Code in 2026. ZUSDURI's peak sales are anticipated at $1 billion by 2030, with a four-year ramp, but near-term revenue guidance will not be provided until at least Q2–Q3 2026. URGN's liquidity improved to $245.5 million after a revised Pharmakon loan, yet cash burn remains high and ZUSDURI's commercial success is critical for financial stability.

UroGen Pharma Ltd. (URGN) Q4 2025 Earnings Call Transcript

Urogen Pharma (URGN) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.66. This compares to a loss of $0.8 per share a year ago.

Commercial launch is on-track for ZUSDURI™, the first and only FDA-approved medication for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC); net sales in 2025 were $15.8 million, reflecting the initial launch period ahead of the permanent J Code Permanent J Code for ZUSDURI became effective on January 1, 2026, streamlining reimbursement procedures and supporting broader patient access JELMYTO ® achieved net product sales of $94 million in 2025, representing year-over-year underlying demand sales growth of 7% Announced refinancing of existing term loan with Pharmakon Advisors that provides additional non-dilutive capital at more favorable terms Conference call and webcast to be held today at 10:00 AM ET PRINCETON, N.J., March 02, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.

Opportunistic refinancing meaningfully reduces cost of capital with 8.25% fixed interest rate and extends amortization period to Q1 2030

• EORTC Recurrence Score Analysis from the Pivotal ENVISION Trial to be Presented at the 2026 American Society of Clinical Oncology's Genitourinary Cancers Symposium (ASCO-GU 2026) PRINCETON, N.J., Feb. 27, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.

PRINCETON, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that management will present at the TD Cowen 46th Annual Health Care Conference to take place March 2-4, 2026.